DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
16.49
+0.41 (2.55%)
At close: Jul 10, 2026, 4:00 PM EDT
16.61
+0.12 (0.73%)
After-hours: Jul 10, 2026, 4:10 PM EDT
DBV Technologies Revenue
DBV Technologies had revenue of $900.00K in the quarter ending March 31, 2026, with 12.50% growth. This brings the company's revenue in the last twelve months to $5.14M, up 69.44% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$5.14M
Revenue Growth
+69.44%
P/S Ratio
168.21
Revenue / Employee
$35,627
Employees
161
Market Cap
964.84M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Lexicon Pharmaceuticals | 69.64M |
| Inventiva | 7.94M |
DBVT News
- 5 days ago - DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - Finanz Nachrichten
- 5 days ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 5 days ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - Wallstreet:Online
- 11 days ago - DBVT, DBV Technologies Updates Biologics License Application Progress - GuruFocus
- 11 days ago - DBV Technologies pushout adds ‘timing risk, not data risk,’ says H.C. Wainwright - TheFly
- 11 days ago - DBVT: Analyst Maintains Overweight Rating with Revised Application Timeline - GuruFocus
- 11 days ago - Cantor stays bullish on DBV despite one month filing delay - TheFly
- 11 days ago - Optimism Surrounding DBV Technologies (DBVT) Despite Submission Delay - GuruFocus